AI assistant
Spyre Therapeutics, Inc. — Director's Dealing 2016
Apr 7, 2016
32226_dirs_2016-04-06_f05c1522-cba3-42fe-956d-eb288d8babee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-06
Reporting Person: York Charles N II (Chief Financial Officer and VP)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7504 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $0 | Common Stock (9523) | Indirect | ||
| Series B Preferred Stock | $0 | Common Stock (2037) | Indirect | ||
| Series B Preferred Stock | $0 | Common Stock (1324) | Direct | ||
| Employee Stock Option (right to buy) | $3.465 | 2025-03-31 | Common Stock (10183) | Direct | |
| Employee Stock Option (right to buy) | $3.465 | 2025-03-31 | Common Stock (22258) | Direct | |
| Employee Stock Option (right to buy) | $3.465 | 2025-03-31 | Common Stock (15027) | Direct |
Footnotes
F1: Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
F2: The stock option vested and became exercisable as to 25% of the shares subject to the option on July 16, 2015, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F3: The stock option vested and became exercisable as to 25% of the shares subject to the option on March 20, 2016, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F4: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 20, 2017, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.